Beyond EGFR, our study also assessed the mutation rates in other reference genes, including KRAS, ALK, ROS1, HER2, RET, MET, NTRK1, NTRK2, and NTRK3, which play essential roles in regulating cell growth and tumor progression in patients with lung adenocarcinoma. This evidence concerns the gene ERBB2 and neoplasm.